INTRODUCTION
Systemic sclerosis (SSc) is a systemic autoimmune disease that often leads to fibrosis in multiple organs, including the skin, heart, vasculature and lungs. Progressive organ fibrosis, particularly in the vasculature and lungs, is a major contributor to scleroderma mortality [1] . There are several mechanisms that contribute to fibrosis in SSc patients including endothelial dysfunction, innate and adaptive immune responses, endoplasmic reticulum stress and fibroblast activation [2] . SSc is not typically considered a disease of aging, but in a recent large United States cohort, the peak incidence for SSc was between 45 and 64 years of age [3] . Older patients with SSc have increased mortality [4, 5] , and patients who present at an older age (>65 years) are at increased risk of pulmonary hypertension, muscle weakness, renal impairment, pulmonary disease and cardiac disease [6, 7] .
Much of the literature on fibrosis and aging comes from studies examining other fibrotic diseases, specifically idiopathic pulmonary fibrosis (IPF). IPF is a disease that causes progressive lung fibrosis and is seen almost exclusively in the elderly population [8] . The patterns of lung disease seen in SSc and IPF are often different. In IPF, the defining histopathologic pattern is usual interstitial pneumonitis. In SSc patients, a pattern of nonspecific interstitial pneumonitis is more common, although usual interstitial pneumonitis is seen in more advanced cases [9] . Despite these differences, both SSc and IPF share many pathobiologic features; these include epithelial and endothelial injury, immune dysregulation and activated fibroblasts with increased deposition of extracellular matrix [10] .
Several hallmarks of cellular aging have been proposed including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and altered intercellular communication [11] [12] [13] . In this manuscript, we explore associations between aging and the pathogenesis of SSc. In particular, we focus on recent studies that highlight the potential
IMMUNE DYSREGULATION
There is growing evidence of age-related changes in the immune system that lead to immunosenescence [14] [15] [16] . These changes occur in both the innate and adaptive immune systems, and increase susceptibility to infection while decreasing tolerance to self-antigens. Immunosenescence may promote fibrosis in several ways. Immunosenescence can lead to a chronic proinflammatory environment ('inflamm-aging') with increased production of cytokines such as IL-6 and TNFa, and increased levels of neutrophils with enhanced production of reactive oxygen species (ROS). There are also agerelated changes in lymphocyte function that might promote a profibrotic environment [16] .
There is limited evidence demonstrating a role for immunosenescence in the pathogenesis of SSc. It has been shown that patients with diverse autoimmune disorders, including SSc, are characterized by accelerated aging of the immune system with A decline in T-cell excision circle (TREC) numbers, suggesting increased thymic involution; loss of CD28 expression on both CD4þ and CD8þ T-lymphocytes is a marker of premature aging of lymphocytes in patients with autoimmune disease [17] . These CD28 null cells are terminally differentiated memory T-cells that are cytotoxic and proinflammatory, and are resistant to apoptosis [ Our understanding of immunosenescence and how age-related changes in both the innate and adaptive immune systems promote fibrosis is still evolving. Understanding how aging triggers selftolerance, impairs resolution of inflammation and the development/progression of fibrosis will likely to be pivotal in developing novel therapeutics that prevent/impede fibrosis.
EPIGENETIC MODIFICATIONS
Epigenetic modifications regulate gene expression without changes to the DNA sequence; these include changes in chromatin structure by DNA methylation and histone modifications, as well as changes to coding and noncoding RNAs. There are examples across multiple species that epigenetic modifications influence longevity, aging and agerelated diseases [22] .
There is increasing evidence for a role of epigenetic modifications in the pathogenesis of SSc. DNA methylation abnormalities have been demonstrated in fibroblasts, endothelial cells and lymphocytes isolated from SSc patients, and histone modifications have been reported in fibroblasts and B-lymphocytes [23] . There is also increasing evidence of a role of miRNAs in the pathogenesis of SSc [23] .
Sirtuin-1 (Sirt1) is a class III histone deacetylase that regulates the transcription of a large number of genes, primarily through transcriptional repression 
KEY POINTS
Aging is associated with worse outcomes and increased mortality in SSc.
Cellular processes such as immune dysregulation, epigenetic modifications, senescence, mitochondrial dysfunction and impaired autophagy may contribute to the genesis and/or progression of inflammation and fibrosis associated with SSc.
Further studies are required to define specific roles of aging phenotypes/hallmarks in SSc-associated vasculopathy, inflammation and fibrosis. [34] recently demonstrated that Wnt signaling is increased in leukocytes and fibroblasts of SSc patients by epigenetic down-regulation of the Wnt antagonists, DKK1 and SFRP1; pharmacologic inhibition of methylation-induced silencing of these antagonists led to a decrease in Wnt signaling.
In summary, age-associated epigenetic modifications can lead to activation of SSc fibroblasts to promote fibrosis. Understanding the role of epigenetic modifications in SSc has the potential to lead to novel antifibrotic therapies.
CELLULAR SENESCENCE
Senescence is a complex process that is defined by an acquisition of irreversible growth arrest; importantly, the accumulation of senescent cells in aging and age-related diseases may have profound implications for tissue homeostasis [35] . Critical to the pleiotropic actions of senescent cells is the maintenance of high metabolic activity and elaboration of senescence-associated secretory phenotype. Interestingly, the senescence-associated secretory phenotype associated with senescent fibroblasts has been suggested to promote termination of the wound healing response and mediate antifibrotic effects in animal models of liver fibrosis [36] . In contrast, Hecker et al. [30 & ] showed that in aged mice with bleomycin-induced lung injury, accumulation of senescent and apoptosis-resistant myofibroblasts is associated with nonresolving fibrosis up to 4 months following injury. In this study, senescence of myofibroblasts was shown to be mediated by an up-regulation of the ROS-generating enzyme, Nox4, and an impaired activation of the Nrf2 antioxidant response pathway; this redox imbalance leads to prolonged senescence and apoptosis resistance leading to persistent fibrosis. Thus, it is important to recognize the differences between acute and chronic senescence in the context of tissue injury-repair [37] . Currently, there are limited studies of the role of cellular senescence in the different cell types, including endothelial cells, fibroblasts and immune cells that participate in the pathogenesis of SSc; future studies in this area may provide additional clues to the specific role(s) of senescence in SSc-associated skin and lung fibrosis [38] .
MITOCHONDRIAL DYSFUNCTION
Decreases in mitochondrial number and mass, changes in mitochondrial DNA and protein levels, and decline in respiratory capacity have all been described in normal aging [39, 40] . It is unclear whether this renders cells vulnerable to stress and contributes to disease processes in aging individuals or whether this is a survival mechanism in reparative/regenerative cells [40] . There is increasing evidence that mitochondria-generated ROS (mtROS) is important in the pathogenesis of fibrosis [11] .
PTEN-induced putative kinase 1 (PINK1) is required for the induction of mitochondrial autophagy (mitophagy) and clearance of damaged/ dysfunctional mitochondria. When mitochondria become depolarized, PINK1 accumulates on the surface and begins a signaling cascade that leads to mitophagy [41] . PINK1 is also critical for normal mitochondrial function and a deficiency in PINK1 has been linked to dysfunction of the electron transport chain, increased oxidative stress and cellular apoptosis [42 && ]. Recent evidence indicates that PINK1 and mitochondrial dysfunction contribute to the pathogenesis of pulmonary fibrosis. Bueno et al. [42 && ] demonstrated that type II alveolar epithelial cells (AECII) from patients with IPF have accumulation of dysfunctional mitochondria and impaired mitophagy; this correlated with decreased levels of PINK1, and PINK1 silencing in normal lung epithelial cells resulted in a profibrotic phenotype. This study also demonstrated that mitochondrial dysfunction led to increased endoplastic reticulum stress, vulnerability to AECII apoptosis and fibrosis. In a related study, Patel et al. [43 && ] reported that PINK1 knockout mice are more susceptible to bleomycin-induced lung fibrosis. Although these authors also found evidence of mitochondrial dysfunction in IPF lungs, they report increased levels of PINK1 in whole lung tissues from IPF lungs. Furthermore, this study demonstrated that these effects could be induced by TGFb-mediated increases in mtROS; scavenging of mtROS ameliorated these mitochondrial abnormalities.
Increased production of mtROS may contribute to mitochondrial dysfunction through other mechanisms. It was recently demonstrated that in bleomycin-induced pulmonary fibrosis in Wistar rats, there is acquisition of mtDNA deletions, respiratory chain dysfunction and mtROS production during the development of pulmonary fibrosis [44] . Similarly, Song et al. [45] demonstrated that inhibition of H 2 O 2 or bleomycin-induced mtROS production by astaxanthin prevents AECII apoptosis, which may mitigate fibrotic responses.
There is a growing body of evidence linking mitochondrial dysfunction to the development of fibrosis. There are limited data on the role of mitochondrial dysfunction in the pathogenesis of SSc-associated fibrosis and other autoimmune diseases, and further research in this area is needed.
IMPAIRED AUTOPHAGY
Autophagy is a cellular process whereby intrinsic damaged organelles/proteins or invading pathogens are targeted for lysosomal degradation [46] . Autophagy is important in aging because an accumulation of damaged and dysfunctional organelles/proteins occurs during a cell's lifetime. Therefore, active and effective autophagy is needed for clearance of these abnormal proteins to maintain healthy cellular functions, and enhancing autophagy can promote delayed cell aging [47] . There is increasing evidence that defective autophagy might play a role in fibrosis associated with both IPF and autoimmune diseases [48] [49] [50] .
Recent studies support a role for impaired autophagy in lung fibrosis. Cabrera et al. ] demonstrated that the phenotype of SSc skin fibroblasts and fibroblasts from older patients share similarities; for example, both groups expressed minichromosome maintenance (MCM) helicase proteins to a lesser degree than young, normal skin fibroblasts. This study showed that decreased MCM7 is associated with reduced autophagy, decreased proliferation and increased accumulation of intracellular proteins in both aged and SSc skin fibroblasts. These findings lend further support for the hypothesis that SSc exhibits an accelerated aging phenotype.
CONCLUSION
Recent studies provide evidence for aging phenotypes in SSc-associated fibrosis. Aging appears to influence the disease course and mortality in SSc patients, suggesting that aging contributes to disease progression; thus, SSc may be considered a disease process with an accelerated aging phenotype. We have reviewed current evidence for immune dysregulation, epigenetic modifications, cellular senescence, mitochondrial dysfunction and impaired autophagy in the pathogenesis of fibrosis and SSc. Understanding specific roles of these aging-related processes in the altered phenotypes of endothelial cells, immune cells and fibroblasts will provide new opportunities to treat the vasculopathy, inflammation and fibrosis that characterize SSc (Fig. 1) . 
